Validation of a commercial line blot for the detection of serum anti-Ro60 autoantibodies

Pathology. 2022 Dec;54(7):900-903. doi: 10.1016/j.pathol.2022.05.009. Epub 2022 Jul 16.

Abstract

Serum anti-Ro60 is one the most frequently encountered autoantibodies in the diagnostic immunopathology laboratory and in clinical practice. A large variety of assays are available to detect this including the popular multiplex line immunoblot (IB) assay. We evaluated the analytical performance of the IB for anti-Ro60 detection, using the counterimmunoelectrophoresis (CIEP) method as the 'gold standard'. We also undertook a survey of international laboratories, who use the IB, about their reporting practices for anti-Ro60. Using the manufacturer's reported cut-off of 15 units, the IB has an analytical sensitivity of 90.9% and specificity of 99.3% for anti-Ro60 detection. The optimal cut-off to balance sensitivity and specificity was determined to be 5 units with a sensitivity of 100% and specificity of 97.4%. Most laboratories use the manufacturer's specified cut-off (15 units) when determining a positive anti-Ro60 result. Whilst the commercial IB generally performs well, laboratorians need to be mindful of the limitations of IB in detecting antibodies that recognise conformational epitopes and what cut-offs they use. A vast majority of laboratories could potentially miss detection of this clinically important autoantibody.

Keywords: Antibodies; Ro60; SSA; antinuclear antibodies; autoantibodies; line blot.

MeSH terms

  • Antibodies, Antinuclear*
  • Autoantibodies*
  • Humans
  • Immunoblotting
  • Sensitivity and Specificity

Substances

  • Autoantibodies
  • Antibodies, Antinuclear